bioRxivBiochemistryPreprint
Real-time sharing of drug screening data on the NCATS OpenData Portal accelerates translational research
K. R. Brimacombe, P. C. Scully, T. Zhao, R. T. Eastman, X. Hu, K. Wang, M. Backus, B. Baljinnyam, C. Z. Chen, L. Chen, Y. Cheng, D. P. Davis, K. Duerr, T. Eicher, A. Friedman, Y. Fu, K. Gorshkov, H. Guo, Q. M. Hanson, N. Hotaling, Z. Itkin, S. C. Kales, C. Klumpp-Thomas, E. M. Lee, S. Michael, , M. D. Hall
Abstract
The National Center for Advancing Translational Sciences (NCATS) has developed an online open science platform - named the NCATS OpenData Portal (ODP) - for quickly and freely sharing complete NCATS translational datasets via an open-access, user-friendly interface. This paper describes the establishment of the ODP, initially deployed during the COVID-19 crisis, and provides a detailed analysis of COVID-19 drug repurposing screening datasets that served as the first large-scale use case for the platform. Over 10,000 compounds were tested across 17 quantitative high-throughput assays, covering a wide spectrum of the SARS-CoV-2 life cycle. In total, over 87,000 concentration-response curves and 426,000 data points were made publicly available on ODP in near real-time, enabling immediate access to complete datasets. The resource is flexible in accommodating various types and structures of data, and it has already expanded since its launch to host additional datasets for COVID-19, other viruses of pandemic potential, and beyond. The OpenData Portal has been designed as a scalable platform for real-time data sharing across drug discovery campaigns, regardless of disease area, with the overarching goal of accelerating discovery at NCATS, the NIH, and the greater scientific community.
- research focus: drug response / drug discovery
- research focus: benchmarking
- research focus: database / resource
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- No more business as usual: agile and effective responses to emerging pathogen threats require open data and open analytics
Dannon Baker, Marius van den Beek, … Steven Weaver·PLoS PathogensPeer-reviewed·Aug 13, 2020
- Exploring NCATS In-House Biomedical Data for Evidence-based Drug Repurposing
Fang Liu, Andrew C. Patt, … Qian Zhu·PLoS ONEPeer-reviewed·Jan 25, 2024
- Mobilisation and analyses of publicly available SARS-CoV-2 data for pandemic responses
Nadim Rahman, Colman O’Cathail, … Guy Cochrane·Microbial GenomicsPeer-reviewed·Feb 15, 2024
- Drug Repurposing Screen for Compounds Inhibiting the Cytopathic Effect of SARS-CoV-2
C. Z. Chen, P. Shinn, … W. Zheng·bioRxiv·Aug 18, 2020
- A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research
Gergely Zahoránszky-Köhalmi, Vishal B. Siramshetty, … Tudor Ionel Oprea·Journal of Chemical Information and ModelingPeer-reviewed·Jan 20, 2022
- Molecular Property Diagnostic Suite for COVID-19 (MPDSCOVID-19): An open access disease specific drug discovery portal
Lipsa Priyadarsinee, Esther Jamir, … G. Narahari Sastry·bioRxiv·Aug 29, 2023